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Abstract
Background: For people with opioid dependence in Norway, chronic hepatitis C virus (HCV) infections contribute
to high mortality and high morbidity. Around 50% of patients in medically assisted rehabilitation (MAR) have been
shown to have HCV, and the current prevention and control efforts have been mostly unsuccessful. Thus, there is a
need for new strategies for people-centred service delivery and innovative methods to improve health outcomes.
Methods: Over the last few years, the city of Bergen, Norway, has developed a cross-sector collaboration with
substantial peer involvement in research and health provision related to substance use. User group representatives
for people receiving MAR, addiction medicine health personnel, infectious disease specialists, policy makers in the
municipality, low-threshold health care centres for people with substance use disorders in Bergen Municipality and
researchers in the INTRO-HCV project have made concerted efforts in this regard. We will present here some of the
strategies and steps we have taken.
Results: We have established an integrated HCV treatment scheme for people who inject drugs or who have
opioid dependence. More than 800 persons have been tested for HCV within these frames, and more than 250
persons have been given treatment for HCV within the project. The integrated treatment of HCV is offered both in
MAR outpatient clinics, municipal low-threshold healthcare centres, and local and regional prisons. The preliminary
results indicate an increase in HCV treatment uptake among those receiving integrated treatment (96% initiating
treatment compared to 75%). The user group organisation ProLAR Nett has established an outreach service to
screen for HCV, increase awareness and reduce the proportion of people unknowingly living with HCV while
informing and motivating people to receive treatment. Together with the other stake holders, peer user group,
health care, research planning, concert events, and policy panels have been held.
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Conclusions: Peer involvement seems to have increased testing rates for HCV and acknowledgment of its
importance. This seems to have improved health care for people with opioid dependence in Bergen over the last
few years, particularly relating to the treatment of HCV. These experiences might be helpful in the planning of
integrated policies in other settings that seek to eliminate the HCV endemic.
Keywords: Chronic hepatitis C, Opiate substitution treatment, Integrated health care, Substance abuse treatment
centers
Background
In addition to overdose deaths [1], people with opioid
dependence in Norway have suffered from high co-
morbidities including chronic hepatitis C virus infections
(HCV) [2]. HCV and hepatitis B are among the leading
causes of liver disease and transplantation worldwide
[3–5], and HCV substantially increases the risk of severe
complications such as liver failure and early death [6, 7].
Among people with HCV, about a third develops severe
hepatic complications within three decades [8]. Among
people with HCV and opioid dependence, liver disease
and overdose have the same case fatality risk after the
age of 50 years [9].
Around 50% of the patients receiving medically
assisted rehabilitation (MAR) are infected by HCV ac-
cording to reports from outpatient clinics that provide
opioid agonist therapy (OAT) as part of the MAR
programme in Norway [10]. The mean age of MAR pa-
tients in Norway is 42 years, and the population is aging
[11]. Many patients have had HCV for more than 20
years. Reaching these patients with treatment is of crit-
ical importance to avoid early deaths and reduced qual-
ity of life, as well as for preventing large costs for future
treatment of end-stage liver disease. Over the last several
years, the development of highly effective tablet-based
direct-acting antiviral medications, has radically changed
HCV treatment [12, 13]. These antivirals are usually
curative within 8 to 12 weeks and most experience few
side-effects. However, utilisation of standard care is low
among people in need of HCV treatment in Norway and
the majority have until recently remained untreated [14].
The high burden of HCV is among the greatest chal-
lenges among people who inject drugs. This group is
also underrepresented in clinical research.
Despite recent advances, the prevention and control of
HCV remains difficult. The World Hepatitis Summit in
São Paulo expressed concern over the lack of integrated
approaches, acknowledging the need for innovative strat-
egies for people-centred service delivery [15]. An editor-
ial from 2017 points out that there is very little research
on user involvement in substance use related research
[16]. Still, there are several good arguments for why user
involvement could be important. People who might be
affected by the research should be listened to and
involved when possible, and user representatives experi-
ences might improve how study participation is per-
ceived. This is important for research quality and for
reducing loss to follow-up. User involvement might also
aid in study implementation and in putting the research
into context and increasing its relevance.
Since 2014, Bergen has gradually increased peer in-
volvement and established an integrated treatment
scheme for HCV in order to improve the health of
people with opioid dependence and people who inject
drugs in Bergen, Norway. We will here present some of
the strategies and steps we have taken and some of the
results of this work.
Methods
We have established a cross-sector collaboration be-
tween peer groups, primary and secondary health care,
policy makers and researchers with peer involvement as
a core component. We will here summarise the con-
certed efforts and the role of the different stakeholders
(see also Table 1 and Fig. 1).
Integrated specialised health care and low thresholds
The Department of Addiction Medicine at Haukeland
University Hospital in Bergen, Norway, developed the
Bergen model of MAR, which is an integrated treatment
and care model for patients with opioid dependence.
Firstly, the evidence indicates that OAT is the preferred
treatment with the best outcomes for people with opioid
dependence [17]. Secondly, lowered barriers to OAT ac-
cess are expected to limit the illegal opioid market and
thus reduce the recruitment of new opioid users, and re-
duce the number of opioid overdose deaths [18]. The
model is based on several principles and treatment ele-
ments, and the services are decentralised and
community-based in order to optimise access for pa-
tients often hard to reach. In Bergen, several MAR out-
patient clinics have been established across the city.
Every month, the MAR clinics have a mean of 12 out-
patient clinic visits per patient and serve approximately
500–600 patients. Patients are followed up by a multidis-
ciplinary team, and each of the MAR outpatient clinics
is staffed by teams specialised in addiction healthcare,
including physicians, nurses, social workers and clinical
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psychologists. These teams provide both non-
pharmacological and psychosocial follow-up closely
linked to pharmacological interventions. In addition,
user group representatives are also being employed to
aid in follow-up at the clinics. Health care and social
workers meet many of the patients on an almost daily
basis with observed intake of the MAR medications [19].
This group of patients often has multiple severe drug
disorders and significant co-morbidity and has only to a
limited degree been able to access other standard health
care services. Treatment is given with frequent clinical
follow-up often involving outpatient visits several days
per week. Further, consultations and follow-up have
been organised using a drop-in approach and limited
use of scheduled appointments and urine screening tests.
Together with municipal low-threshold health care cen-
tres, a programme has deployed nasal naloxone for treat-
ment of overdoses. A collaboration has also been
Fig. 1 Photos from some of the responses mentioned in the paper including some of the newspaper stories and the outreach bus
used («Hepatittbussen»)
Table 1 Table summarising the collaborative and concerted efforts
Information interventions Outreach interventions Integrated health care
Interventions
towards users
User group seminars led by user group
representatives together with MAR clinics
and the INTRO-HCV project
Information brochure developed by
user group representatives and the
INTRO-HCV project reaching 6000
persons
Establishing of outreach bus
(«Hepatittbussen») led by user group
representatives in ProLAR Nett to
diagnose people with hepatitis C,
informing and motivating for
treatment
Establishing an integrated health care
response in collaboration between user
group representatives, MAR clinics,
internal medicine specialists, municipal
health care clinics and researchers
coordinated by INTRO-HCV project. The
integrated assessment and treatment
has reached 800 persons in MAR out
patient clinics, municipal health care




User group members working in MAR clinics
and health care seminars led by MAR clinics,
the INTRO-HCV project and user group
representatives
Research planning seminars led by
INTRO-HCV project in collaboration with
user group representatives, MAR clinics,
and municipal health care officials.





The concert «Lever4Livet» reached a general
population group in the Bergen area
Policy panels led by municipal health
care policy makers with user group
representatives
Several mass media communications
and have reached a large population
group in the Bergen area
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established with infectious disease specialists at the De-
partment of Internal Medicine at Haukeland University
Hospital to facilitate the integrated treatment of HCV
(see more details below). As foundation for the inte-
grated treatment, competence building among clinicians
and user groups and flexibility to adapt to initially differ-
ent routines have been emphasised. The Department of
Addiction Medicine has further established two advisory
boards in order to include user experiences in the devel-
opment of the services. The advisory boards meet every
seventh week with directors and administrative leaders.
One of the outcomes from this has been the employ-
ment of people with user experiences in the MAR clinics
in order to improve the user orientation of the services.
Integration of health care and research
As part of this treatment model in Bergen, we are now
testing further scale-up strategies for the integrated
treatment of people with HCV with opioid dependence
or people who inject drugs in order to end the HCV en-
demic among people who inject drug in Norway. More
specifically, the aim is to improve the health of a vulner-
able group while reducing the risk of disease transmis-
sion within the population. Further, we aim to gather
evidence on the health of people who inject drugs which
traditionally have been difficult to obtain, including the
incidence of HCV and how treatment approaches impact
HCV incidence [20]. The Bergen Addiction Research
group (BAR) has initiated the INTRO-HCV study com-
paring the efficacy of integrated treatment of HCV
within the MAR clinics and the low-threshold health
care centres [21, 22]. INTRO-HCV is a multicentre, ran-
domised controlled clinical trial without pharmaceutical
industry involvement. The intervention involves inte-
grating diagnostic and treatment follow-up for HCV
treatment into the MAR treatment that patients receive
in outpatient clinics including testing for HCV, counsel-
ling and treatment evaluation and treatment delivery.
For people followed up in municipal low-threshold
health care centres, integrated treatment will be given in
a more “tailored” and individualised manner, linked to
the health care they receive from the municipal centres.
The main endpoint is sustained virologic response of
HCV at 12 weeks after treatment and participants will be
screened for hepatitis C at least annually for the total
study duration between 2017 and 2021 (a detailed trial
description is found in the study protocol [22]). The sur-
veillance also includes several health indicators such as
quality of life, mental health symptoms, and the presence
of other diseases in need of treatment. To triangulate
the outcome data, we will also analyse Norwegian regis-
try data (including the Norwegian prescription registry)
to assess uptake of treatment for hepatitis C infection.
This study will provide evidence for the relative
advantages and disadvantages of integrating a treatment
programme for HCV into MAR or low-threshold care
compared to standard care aiming to increase access to
treatment and to improve treatment adherence. If the
integrated treatment structure is found to be safe and ef-
ficacious, it can be considered for further scale-up.
Peer involvement
The ProLAR Nett user group members have had a
strong focus on HCV. With this focus, they have had an
important role as research partners and worked closely
with clinicians and policy makers. The user group organ-
isation has taken the initiative and establish and organise
an outreach bus service (“Hepatittbussen”) to test for
HCV, focusing on awareness with an objective of redu-
cing the proportion of people unknowingly living with
HCV while informing and motivating for treatment. The
bus has been used since 2018 and is planning to reach
1500 people with information and screening for HCV
[23]. The background for using a mobile treatment clinic
is to be a low-threshold service in order to improve ac-
cess for people struggling to make use of regular hospital
clinic services. The service has gotten attention in the
mass media and has contributed to increasing awareness
around HCV. The bus is staffed with a trained nurse
and user group personnel, and it uses instant antibody
screening tests. The user involvement is also regarded as
important to improve how the services reach the user
group. To increase knowledge on HCV, the user group
organisation has built a web page with extensive infor-
mation and short films presenting stories of people liv-
ing with HCV (hepc.no). The web page also includes a
contact form for people to send questions to a gastro-
enterologist/hepatologist. An information brochure that
is given to people with substance use has been developed
by ProLAR Nett together with INTRO-HCV project (see
Additional file 1). Further, the user organisation has also
contributed to several workshops with the European
Liver Patient Association [24].
Collaboration across sectors and delivery platforms
A close cooperation has also been established between
the Department of Addiction Medicine and the Agency
for Mental Health and Substance Abuse Services in Ber-
gen municipality, which is responsible for the care in
low-threshold health care centres in Bergen providing
care for people with substance use disorders. In 2017,
the policy makers in Bergen adopted an action plan for
preventing overdose deaths. One of the important mea-
sures in this plan is to offer testing and integrated treat-
ment of HCV to people who inject drugs. According to
Norwegian guidelines, OAT is given by secondary health
care while people with opioid dependence at high risk of
overdose are given health care mostly by primary health
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care providers, including municipal providers. In
many Norwegian settings, there is a risk of uncoor-
dinated health care in these cases. In Bergen, munici-
pal providers and secondary health care have worked
together with peer involvement to avoid such gaps.
As a political response to these challenges, the Bergen
community council established a drug policy advisory
board where they elected a group consisting of repre-
sentatives from civil society including members of
user organisations, next-of-kin organisations, and
non-governmental organisations working with sub-
stance use disorders. The advisory board meets every
six weeks with local politicians. The advisory board is
invited to give guidance to on-going drug-related de-
bates based on their experiences.
Results
To date, the outreach bus has reached around 500
persons and 200 of these persons have been tested
for HCV with rapid tests for HCV RNA in addition
to being assessed for liver fibrosis with mobile elasto-
graphy. Many of these have been linked up to further
follow-up for prompt HCV treatment. The informa-
tion brochure has been provided to eight MAR clinics
and low-threshold clinics in Bergen and directly to
people living with HCV and has reached 2000 users
in Bergen and 4000 elsewhere in Norway. Through
the web page, contact persons have been contacted
by substance users, family members and healthcare
professionals wanting to learn more about treatment
options and prognosis, and this contributed to
debunking many myths around HCV. The user union
representatives have been interviewed more than ten
times in national and local media such as newspapers
and television and have thus contributed to awareness
about the barriers to access to treatment.
ProLAR Nett started with user to user information
courses and conducted around ten peer seminars at
the MAR clinics and contributed to health care semi-
nars led by the clinics and the research project
INTRO-HCV. User group representatives also gave a
number of presentations to different professional
groups including policy makers and healthcare and
social workers. The user group and INTRO-HCV also
arranged a concert to communicate to the people in
Bergen with famous artists including Phil Spalding
(“Lever4Livet” [Living/Liver4Life]).
The involvement of peer representatives in the advis-
ory board of the Bergen Municipality Council contrib-
uted to the restructuring of the former injection room to
allow for safer substance use patterns such as smoking,
nasal and oral intake rather than only injecting drugs.
Further, the injection room initially offered observation
of only heroin use, but after the change offered
observation also to people using other drugs or a com-
bination of substances. Bergen Municipality and policy
makers have also developed an extensive policy docu-
ment on the management of substance use [25].
Through the INTRO-HCV project, around 800 pa-
tients receiving OAT have been tested for HCV and
other morbidities. More than 250 persons found to have
chronic HCV have been treated within the project. The
preliminary results indicate an increase in HCV treat-
ment uptake among those receiving integrated treatment
(96% initiating treatment compared to 75%). The assess-
ment has also contributed to diagnosing infections such
as syphilis, low thyroid levels, vitamin deficiencies,
etcetera.
During the implementation of the efforts mentioned
we faced several challenges that we managed to over-
come (see Table 2).
Discussion
To optimise health services for people with substance
use disorders, new approaches seem to be required,
and using a model of health care focusing on inter-
disciplinarity and accessibility with decentralised and
frequent follow-ups have been suggested to be effect-
ive [26–28]. Our collaboration between healthcare
workers, researchers and user group members has
been experienced as fundamental in order to increase
trust and mutual understanding, to increase know-
ledge among healthcare workers, policy makers and
users, and to break down barriers and stigma. Some
of the key components of our efforts are the inte-
grated health care response, establishing of user group
panels, holding health care and user seminars, arran-
ging concerts, use of mass media, and use of an out-
reach bus service. These efforts have substantially
increased testing and treatment for HCV, but also im-
proved identification of other health problems in need
of follow-up and treatment. User involvement in roles
as research collaborators have contributed to aiding
feasibility of study implementation and also helps us
in putting the research into context.
Conclusion
In summary, the Bergen collaborative model has used
new approaches aiming to reduce opioid dependence-
related morbidity such as HCV. This model has con-
tributed to improving health care for people with opi-
oid dependence in Bergen over the last few years, and
these experiences might be helpful in other settings
on the path to eliminate the HCV endemic. User in-
volvement has been an essential component in this
regard. Although it is too early to draw a conclusion
regarding the full impact of the Bergen MAR model
with substantial peer involvement, the preliminary
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data are promising. Perhaps the Bergen model and
user group involvement might inspire the develop-
ment of adapted steps leading to improved health
outcomes among people with substance use disorders
– not only for fighting HCV, but also for reducing
opioid dependence-related morbidity and deaths.
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